ABSTRACT: Introduction: More than 90% of amyotrophic lateral sclerosis (ALS) patients have muscle cramps, but evidencebased treatments have not been available. Methods: A multicenter, double-blind, placebo-controlled crossover trial of mexiletine 150 mg twice daily was conducted in ALS patients requesting treatment of symptomatic muscle cramps. Results: Muscle cramp frequency was reduced in 18 of 20 patients; 13 reductions were attributed to treatment (P < 0.05). The average reduction, based on t tests, was 1.8 cramps per day (a reduction from 5.3 with placebo to 3.5 with mexiletine). The estimated reduction of cramp severity was 15 units on a 100-unit scale (P 5 0.01) from a baseline average of 46. No effect on fasciculations was noted. One patient discontinued the study because of dizziness, and another patient discontinued the study to start open-label mexiletine therapy. No serious adverse event occurred. Discussion: Mexiletine is a well tolerated and effective medication for controlling the symptom of muscle cramps in ALS.
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Muscle Nerve 58: [42] [43] [44] [45] [46] [47] [48] 2018 Muscle cramps affect more than 90% of persons with amyotrophic lateral sclerosis (ALS).
1,2 Muscle cramps are sudden, involuntary muscle contractions that result from high-frequency motor unit discharges. 3 Physiologically, the main mechanism behind muscle cramps in ALS is poorly characterized but may result from an increase in persistent sodium ion (Na 1 ) currents of lower motor neurons and changes in potassium ion conductance. 4 The Na 1 increase may be caused by axonal regeneration, collateral sprouting, or changes in Na 1 channel gating. An alternative explanation may be passive membrane changes. 5 In 2003, quinine sulfate was the medication most frequently prescribed by ALS clinicians 6 ; however, in 2006, the US Food and Drug Administration (FDA) prohibited the marketing of quinine sulfate for muscle cramp treatment, citing a lack of documented effect and rare fatalities. 7 Cochrane systematic review found low-quality evidence supporting a reduction in muscle cramps by quinine in contrast to the FDA's view. 8 In 2008, while preparing for the present study, we surveyed 50 ALS clinicians in the United States (members of the Northeast ALS Consortium [NEALS]) regarding muscle cramp treatment. Among responders, 40 physicians reported that they prescribed baclofen and 38 reported prescribing gabapentin; several other agents were used, but only 3 physicians reported that they prescribed mexiletine. As of 2012, no consensus existed on how to treat muscle cramps in ALS. 9, 10 Mexiletine is a Na 1 channel blocker that reduces persistent sodium currents.
11 Threshold tracking peripheral nerve excitability studies that evaluated the membrane properties of the axons at the stimulation site 12 have demonstrated that mexiletine reduces muscle cramps. 13 Mexiletine also markedly reduced muscle cramps as a primary outcome measure in an open-label study of spinocerebellar ataxia type 3. 11 More recently, muscle cramps were measured as a secondary outcome in a study of mexiletine in ALS 14 ; mexiletine was shown to markedly reduce muscle cramp severity and frequency while not having a measurable effect on ALS disease progression. This latter study Additional supporting information may be found online in the Supporting Information section at the end of the article.
Abbreviations: ALS, amyotrophic lateral sclerosis; FDA, US Food and Drug Administration; Na 1 did not select only patients who wanted treatment of muscle cramps. At any time, only a subset of ALS patients want medication treatment for muscle cramps, a fact that possibly reduces the applicability of the result. 12 Factors determining whether an ALS patient wants treatment of muscle cramps are largely unknown, but more severe pain has been associated with the use of prescription medications. 2 Fasciculations are neuromuscular hyperexcitability phenomena and are a hallmark symptom of ALS. No treatment today is proven to be effective against fasciculations. A membrane-stabilizing Na 1 channel blocker such as mexiletine may reduce them, and this outcome has also been explored. At the time of this study, mexiletine had not been evaluated; now, a recent study has provided evidence that it is ineffective. 15 Mexiletine is a medication approved by the FDA for the treatment of cardiac arrhythmias, and typical dosage for this indication is between 200 and 400 mg, 3 times per day. It has a half-life of 10-12 h. Common dose-dependent adverse events have included gastrointestinal distress, lightheadedness, tremor, and coordination difficulties. The present trial sought to determine whether mexiletine reduces the frequency of muscle cramps and the severity of muscle cramps and fasciculations for patients with ALS.
MATERIALS AND METHODS

Participants.
A multicenter, double-blind, within-patient crossover trial was conducted with 20 patients. The major inclusion criteria were ALS diagnosis by modified El Escorial criteria, Awaji version (clinically definitive, probable, or possible) 16 ; wish to treat muscle cramps with medication; and no contraindication to mexiletine, including heart and liver disease. Other medications taken for the expressed purpose of preventing muscle cramps were disallowed. Patients who had 2 or more cramps and were able to complete the diary for 1 week (screening epoch) were randomly assigned in a 1:1 ratio to mexiletine or placebo for their first epoch. The initial power calculation was based on an expected total of 30 patients with ALS entering this 2-treatment (placebo and mexiletine) crossover study and an expected <10% drop-out rate resulting in 27 patients completing the study. The primary statistical outcome of the trial was the within-subject difference in number of cramps on each treatment. Using the gabapentin trial conducted by the WALS group 17 we had modeled that if the true difference between treatments was on average 1.2 cramps per day (23% reduction from 5.6 to 4.3 in treated vs. no reduction in placebo) the trial would have an 80% power to detect a treatment difference by using a 2-sided 5% significance level. This conclusion was based on the assumption that the within-patient standard deviation of the response variable was 1.55, the same within-patient standard deviation observed in the gabapentin trial. Study enrollment was halted at 23 patients randomly assigned to treatment because of slow enrollment, time constraints in the form of contract expiration, and the larger cramp frequency effect size (269%) seen by Weiss et al.
14
Protocols. Randomization was stratified by riluzole use. The Excel (Microsoft, Redmond, WA) random number generator randbetween was used to generate the sequence of randomized treatment assignments. The study statistician (D.M.) generated the allocation sequence, the blinded investigators and study personnel enrolled participants, and the blinded study pharmacist dispensed the interventions. After the 1-week screening period, patients were randomly assigned to treatment. For days 1-3, patients took study-blinded capsules once at bedtime, and for days 4-14 patients took study capsules twice daily. Identical-appearing study capsules contained placebo or mexiletine 150 mg (prepared by University of Iowa Pharmaceuticals, Iowa City, IA). Each treatment epoch was 2 weeks with an intervening 1-week washout for a minimum trial duration of 6 weeks including the screening week.
Electrocardiography was performed, and liver enzymes were tested for safety 3 times (screening epoch, end of epoch 1, and end of epoch 2). In larger populations with longer and higher exposure to mexiletine, disturbances in liver functions have been reported. Among patients with known cardiac conduction defects, electrocardiographic changes have been known to develop.
Patients were enrolled at the University of California sites in Davis, Irvine, San Diego, and Los Angeles, and 1 patient participated by telemedicine. Telemedicine participation via visits at a local physician's office by using a videoconferencing system (Polycom, San Jose, CA) to communicate with the University of California, Davis study team was offered to all ALS patients in California. A telemedicine patient's physical examination and safety monitoring could be performed at the patient's local physician's office. The telemedicine study was advertised through local support groups, newsletters from the ALS Association and the Muscular Dystrophy Association, PatientsLikeMe, and the research notification system from the Agency for Toxic Substances and Disease Registry throughout the state. In addition, this trial was registered on ClinicalTrials.gov (NCT01811355) and online at trial recruitment sites, including NEALS and the ALS Therapy Development Institute.
The trial was approved by the University of California, Davis, Institutional Review Board in February 2013; the other University of California sites relied on University of California, Davis, as a central institutional review board. Trial enrollment was completed in December 2015. All patients signed written informed consent and received no stipend for study participation. All procedures were in accordance with the ethics standards of the responsible committee on human research and with the Helsinki Declaration of 1975, as revised in 1983. Data on race/ethnicity were collected to comply with National Institutes of Health guidelines; race/ethnicity was self-identified by the patients.
Outcome Measure. The primary outcome measure was daily muscle cramp count, completed by the patient at bedtime. All muscle cramps in the preceding 24 h were recorded. Daily counts of muscle cramps have excellent face validity and have been shown to be responsive to clinical change 14 We also used a daily, self-administered, 100-unit visual analog scale (VAS) to rate the severity of muscle cramps. This global severity rating scale comprised all aspects of the muscle cramps, including frequency, duration, and intensity. In addition, a global severity rating of fasciculations was collected and contained all aspects of fasciculations, including frequency and intensity. For global severity of muscle cramps and fasciculations, higher VAS numbers represented more severe symptoms. Muscle cramp severity scales have good face validity and have been shown to detect clinical change in several studies. 14, 18 Fasciculation ratings have been used previously. 19 Patients were educated by study personnel and received an informational handout to help differentiate cramps, fasciculations, and spasticity.
Statistical Analysis. Data from each epoch were evaluated by using 3 methods. Mean responses of drug versus placebo were compared by using a paired t test for each participant. Next, a linear mixed-effects model was fitted to estimate the treatment effects on the measures. The model included terms for fixed effects, a constant, a placebo, and a drug difference effect. Random effects were added to allow for different constants and different placebo and drug effects of each participant. The fixed drug difference effect was tested against zero to determine whether treatment with mexiletine reduced number of muscle cramps and severity of muscle cramps and fasciculations. Finally, data of each patient were condensed to mean and median for each treatment. We used the pkcross function (StataCorp, College Station, TX), specifically designed for crossover data, to test for treatment, period, and order of treatment effects. Analyses were performed in Stata software version 12 (StataCorp.
RESULTS
Baseline patient characteristics are summarized in Table 1 . Among 28 patients who signed consent, 5 did not meet inclusion criteria because of past myocardial infarction (n 5 1), long QT syndrome (n 5 1), AV block (n 5 1), no muscle cramps (n 5 1), or hospitalization during the screening period that resulted in inability to complete a screening diary and follow-up (n 5 1; Fig. 1 ). Twenty-three patients were randomly assigned to treatment; 21 patients completed the study, but 1 patient did not return the outcome diary, leaving 20 outcome diaries completed for analysis. Among the 2 patients who did not complete the study, 1 patient discontinued mexiletine because of dizziness. This symptom was mild, and the patient was willing to restart the study drug but had not taken it for a period longer than allowed per protocol. Consequently, that patient was withdrawn. One patient had such marked improvement from baseline after the start of the blinded study drug that he was unwilling to withdraw from the drug during washout. This latter patient was prescribed openlabel mexiletine and had continued suppression of muscle cramps. At the end of the study, it was confirmed that the patient had received active drug during his first epoch. A total of 5 patients reported mild adverse effects while taking mexiletine, and 3 reported mild adverse effects while taking placebo ( Table 2 ). The recruitment period for the trial was from July 2013 to December 2015. The protocol did not require that the ALS diagnosis was established in person at a University of California ALS clinic. However, all patients who enrolled in the trial had undergone such an evaluation.
Number of Muscle Cramps. Among the 20 available patients, 18 had reductions in the prespecified primary outcome measure of mean number of muscle cramps when taking mexiletine (Fig. 2) . For 13 patients, results from paired t tests indicated statistically significant reductions (P < 0.05; 9 patients had P < 0.01). The chance probability of 18 of 20 reductions was < 10 210 . Two of the 20 patients had statistically significant increases of muscle cramp counts while receiving mexiletine. Individual patient estimates for treatment effect ranged from a reduction of 7 to an increase of 4 muscle cramps per day. The average reduction, based on paired t tests, over the whole epoch was 1.8 muscle cramps per day (a reduction from 5.3 with placebo to 3.5 with mexiletine). These results were confirmed by the linear mixed-effects model. The standard deviation of the random effect for treatment was 2.3, indicating a high variation in treatment effect. A pkcross analysis of the mean number of muscle cramps for each patient showed a treatment effect (P 5 0.008) but no effect from period (P 5 0.39) or sequence (P 5 0.70) of treatments (Table 3) . No sex effects were tallied; no age effects on cramps were found from mexiletine therapy, but older patients had more cramps (0.6 cramps/day per 
DISCUSSION
We found a reduction of muscle cramps in patients with ALS when they took mexiletine at a dose of 150 mg twice daily compared with placebo. Four patients became completely cramp free, and 18 of the 20 patients completing the trial recorded fewer muscle cramps when taking the dose studied in this trial. The studied dose was well tolerated is considered low in the context of the drug's recommended maximal daily dose of 1,200 mg. The effect of mexiletine on cramps in ALS is consistent with results in a recently published paper from a longer, concurrent parallel arm mexiletine study by Weiss et al.
14 Although an effect of mexiletine on cramps was reported, this study also failed to show that mexiletine had a measurable effect in altering the disease course over a period as short as the present study duration of 2 weeks, making this an unlikely confounder. The notable differences between the study by Weiss et al.
14 and the present study are that (1) muscle cramp frequency was the primary outcome in the present study, (2) a shorter treatment duration of 2 weeks was studied by our group versus a longer treatment duration of 12 weeks, and (3) more restrictive inclusion criteria were used in the study by Weiss and colleagues, including disease duration <3 years and vital capacity >50%. In an attempt to make the results generalizable to the ALS clinic population with muscle cramps, we enrolled ALS patients who wanted medication treatment of muscle cramps and applied few exclusion criteria. With regard to dosage, the number of participants exposed to the 150-mg twice daily dose of mexiletine was 20 in both randomized placebocontrolled studies. Weiss et al.
14 also evaluated a higher mexiletine dose of 900 mg per day, which was intolerable to 32% of patients but had an even greater effect in controlling muscle cramps. It is our opinion that a symptomatic cramp treatment should be well tolerated and restricted to patients with cramps that the patients believe warrant treatment, as in the present study. In contrast, a disease-modifying agent might be considered for use by patients even with tolerability problems. We suggest that, in clinical practice, the 150-mg twice daily dose is a reasonable starting dose on the basis of the experience of these 2 studies. This also conforms to our personal experience and practice pattern. The dose can be increased if required and, anecdotally, and as shown in the study by Weiss and colleagues, a higher dose may further reduce muscle cramps if the 150-mg twice daily dose does not provide satisfactory results. Gradually increasing the dose by 150 mg every few days until effect, adverse effects, or the maximal approved dose (1,200 mg/day) is reached is a strategy that we have used clinically. Periodic review of the indication for continued therapy is advised, but our personal experience has been that many patients benefit from treatment until the end of their disease. Prior randomized trials have evaluated muscle cramps as secondary outcomes in ALS trials. They include trials of riluzole, 20, 21 xaliproden, 22 and gabapentin, 17 but the results have been negative. The trial of tetrahydrocannabinol conducted by Weber et al. 19 is the only other prospective randomized trial that has been conducted to evaluate cramps as the primary outcome measure. Their trial used a crossover study method similar to ours, but no effect of tetrahydrocannabinol was seen. To the best of our knowledge, the only positive previous trial with muscle cramps as a primary outcome measure in ALS was an open-label study of levetiracetam. 18 The result of that study has not been replicated in a blinded study, and levetiracetam has not won widespread use. 2 Riluzole, which also blocks persistent Na 1 currents, has not been shown to have an effect on cramps in larger studies. 20, 21 Of particular interest, the combination of mexiletine and riluzole did not appear to have an effect different from what was seen with mexiletine alone in the present study. Differences between the effect of riluzole and of mexiletine on Na 1 currents have been explored, 15 but no definitive conclusions have been reached. This study suggests that modulation of persistent Na 1 currents affected by mexiletine reduces cramp generation, as suggested by electrophysiological studies. 13 The recently FDA-approved drug edaravone was not studied; no known interactions between the 2 drugs exist. Edaravone would not be expected to have an effect on muscle cramps on the basis of its mechanism as a free radical scavenger, but no data have been published.
The lack of an effect of mexiletine on fasciculations is consistent with clinical observations; unfortunately, this symptom currently has no effective treatment option. A recent study using the same dose of mexiletine also supported this finding of no effect of mexiletine on fasciculations. 15 The primary limitation of the present study is the small sample. However, the crossover design enabled us to have sufficient power to detect the effect of mexiletine on cramp number per unit time. Crossover designs can have problems with confounding period and sequence effects, but, in our situation, neither was significant. In the study design, the randomization and crossover among participants should reduce the risk of bias from a differential progression of cramp symptoms, but cramp frequency is known to vary over time. 1, 2 This variability also may explain why 2 participants had increased cramps during the mexiletine phase of the trial. No period effect was observed statistically, arguing that this did not occur.
This study also measured the direct patient experience of muscle cramps and did not use an electrophysiological biomarker such as threshold tracking, which was performed in a prior study of mexiletine. 13 Other types of involuntary muscle contractions or other symptoms may have been misidentified as muscle cramps by the participants in this study, and another objective outcome measure would have been useful to help validate the patient-reported primary outcome measure.
Another limitation of the study is that detailed descriptive information was not collected regarding other symptomatic treatments of cramps or exacerbating factors. For example, we did not try to account for other factors that could affect reported muscle cramps over the short 2-week treatment period, such as specific activities or amount of hydration.
No quality-of-life (QoL) measures were obtained in this study. Although symptomatic treatment seeks to improve the patient's QoL in a global sense, muscle cramps are not measured by generic QoL measures, including the 36-Item Short Form Survey or ALS-specific ones, such as Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 or the ALS-Specific Quality of LifeRevised. Hence, we did not expect to be able to detect a drug effect using a QoL measure.
Our study provided 1 important methodological insight that may be of value beyond the ALS clinical trial community. Contrary to our expectation, only 1 patient participated through telemedicine, despite multiple recruitment strategies to promote such participation.
Mexiletine is an approved medication with more than 10,000 patients monitored in postmarketing studies. As a class Ib antiarrhythmic, it carries a black box warning common to all class I agents derived initially from the Cardiac Arrhythmia Suppression Trial. 23 In that study of patients at 6 days to 2 years after myocardial infarction, increased rates of death and nonfatal cardiac arrest were seen among patients treated with the class Ic agents encainide and flecainide compared with rates seen in placebo-treated patients. This small, short-duration study does not contribute materially to the reported safety of the drug. Prior reports highlight that dose-related adverse events most commonly affect the central nervous system, producing dizziness, or the gastrointestinal system, causing nausea or vomiting. 24 Cardiac conduction is not generally affected for patients with normal conduction (as seen in this study), but, in patients with cardiac conduction defects (excluded from this study), changes can occur. 24 In conclusion, a mexiletine dose of 150 mg orally twice daily was shown in a placebocontrolled randomized clinical trial to reduce the frequency of cramps over the first 2 weeks of treatment, with infrequent adverse effects. Higher doses may provide additional benefit but also more frequent adverse effects. Mexiletine is the only medication shown to reduce muscle cramp frequency and severity in ALS.
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